2. Academic Validation
  3. Synthetic Approaches to the New Drugs Approved During 2015

Synthetic Approaches to the New Drugs Approved During 2015

  • J Med Chem. 2017 Aug 10;60(15):6480-6515. doi: 10.1021/acs.jmedchem.7b00010.
Andrew C Flick 1,  Hong X Ding 2,  Carolyn A Leverett 1,  Robert E Kyne Jr 3,  Kevin K-C Liu 4,  Sarah J Fink 5,  Christopher J O'Donnell 1
Affiliations

Affiliations

  • 1 Groton Laboratories, Pfizer Worldwide Research and Development , 445 Eastern Point Road, Groton, Connecticut 06340, United States.
  • 2 Pharmacodia (Beijing) Co., Ltd. , Beijing, 100085, China.
  • 3 Celgene Corporation , 200 Cambridge Park Drive, Cambridge, Massachusetts 02140, United States.
  • 4 China Novartis Institutes for BioMedical Research Co., Ltd. , Shanghai, 201203, China.
  • 5 BioDuro Co., Ltd. , Shanghai, 200131, China.
PMID: 28421763 DOI: 10.1021/acs.jmedchem.7b00010
Abstract

New drugs introduced to the market every year represent privileged structures for particular biological targets. These new chemical entities (NCEs) provide insight into molecular recognition while serving as leads for designing future new drugs. This annual review describes the most likely process-scale synthetic approaches to 29 new chemical entities (NCEs) that were approved for the first time in 2015.

Figures
Products